Novo Nordisk - Ireland

Company description

General information:
Irish office: 3/4 Upper Pembroke Street, Dublin 2
Global headquarters: Bagsværd, Denmark
Irish workforce: 24 employees
Global workforce: More than 31,300 employees
International production facilities in seven countries
Product areas

Diabetes care
Hormone replacement therapy (HRT)
Haemostasis management

Growth hormone therapy.

Clinical research:
Before any medicine is available for doctors to prescribe, it must be granted a license by the government. Therefore, all medicines have to be tested in appropriate patients to ensure that they reach the standards of safety and efficacy required by governmental agencies around the world. This is achieved by conducting clinical trials in which patients freely volunteer to try new medicines so that relevant data can be obtained. All clinical trials must conform to globally accepted scientific and ethical standards before they can proceed.

Novo Nordisk is committed to ensuring that all its products meet the highest quality standards and are rigorously tested by performing clinical trials in collaboration with doctors and nurses around the world, including sites in Ireland.

Novo Nordisk way:

In 1923, our Danish founders began a journey to change diabetes.

Today, we are thousands of employees across the world with the passion, the skills and the commitment to continue this journey to prevent, treat and ultimately cure diabetes.
Our ambition is to strengthen our leadership in diabetes. Our key contribution is to discover and develop innovative biological medicines and make them accessible to patients throughout the world. We aspire to change possibilities in haemophilia and other serious chronic conditions where we can make a difference. Growing our business and delivering competitive financial results is what allows us to help patients live better lives, offer an attractive return to our shareholders and contribute to our communities.

We never compromise on quality and business ethics

Our business philosophy is one of balancing financial, social and environmental considerations – we call it ‘The Triple Bottom Line’

We are open and honest, ambitious and accountable, and treat everyone with respect
We offer opportunities for our people to realise their potential.
Every day, we must make difficult choices, always keeping in mind, what is best for patients, our employees and our shareholders in the long run.
It’s the Novo Nordisk Way.